Very recently, it has been reported that disialogangliosides, such as GD3 and GD2, enhance EGFR signaling, resulting in the expression of a cancer stem cell phenotype and a reduced sensitivity to Gefitinib [86]. The gene discussed is EGFR; the disease is cancer.